Evidence map›Paper›PMID 40548929›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Nanoscale Metal-Organic Framework-Based Self-Monitoring Oxygen Economizer and ROS Amplifier for Enhanced Radiotherapy-Radiodynamic Therapy.

Shiye Du, Qiang Wen, Ting Han, Jiongyu Ren, Mingyu Wang, Yunpeng Dai, Xiaoguang Ge, Lu Li, Junzhi Liu, Shi Gao

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shiye DuDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Qiang WenDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Ting HanDepartment of Radiotherapy -1 and Department of Radiotherapy -4, Jilin Province Cancer Hospital, Changchun, 130000, China.
Jiongyu RenDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Mingyu WangDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Yunpeng DaiDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Xiaoguang GeDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Lu LiDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Junzhi LiuDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Shi GaoDepartment of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.ORCID https://orcid.org/0000-0002-4692-0115

Funding

Hygiene Specific Subjects of Jilin Province 2021SCZ05Hygiene Specific Subjects of Jilin Province 2022SCZ27Hygiene Specific Subjects of Jilin Province 2024SCZ15Hygiene Specific Subjects of Jilin Province 2024SCZ69National Natural Science Foundation of China 82272033National Natural Science Foundation of China U22A20348
6 · The paper itself

Abstract

Radiotherapy-radiodynamic therapy (RT-RDT) has emerged as a promising approach due to its remarkable anticancer efficacy. However, hypoxic tumor microenvironment and insufficient energy deposition severely reduce the radiotherapy outcomes. Herein, lonidamine (LND)-loaded Fe(III) metal-Pt(II) porphyrin framework (FPTM-LP) is designed for radiosensitization through hypoxia alleviation and reactive oxygen species (ROS) amplification. Specifically, the high-Z element Pt effectively absorbs X-ray photons to generate •OH for RT while transferring X-ray energy to porphyrin (TCPP), which stimulates the generation of

Indexed as

Metal-Organic FrameworksNeoplasmsOxygenRadiotherapyReactive Oxygen SpeciesAnimalsCell Line, TumorHumansMiceMice, Inbred BALB CMice, NudeRadiation-Sensitizing AgentsTumor MicroenvironmentMetal-Organic FrameworksOxygenRadiation-Sensitizing AgentsReactive Oxygen Specieshypoxia reversionmetal‐organic frameworkradiodynamic therapyradiotherapyreactive oxygen species

Identifiers

PMID40548929
PMCPMC12463018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.